Wedbush Analysts Decrease Earnings Estimates for FENC

Fennec Pharmaceuticals Inc (NASDAQ:FENC) – Investment analysts at Wedbush decreased their FY2025 EPS estimates for Fennec Pharmaceuticals in a report issued on Thursday, November 7th. Wedbush analyst D. Nierengarten now anticipates that the company will post earnings of $0.05 per share for the year, down from their previous forecast of $0.06. Wedbush has a “Outperform” rating and a $13.00 price target on the stock. The consensus estimate for Fennec Pharmaceuticals’ current full-year earnings is $0.08 per share. Wedbush also issued estimates for Fennec Pharmaceuticals’ FY2026 earnings at $2.25 EPS.

A number of other equities analysts also recently issued reports on the company. HC Wainwright decreased their price objective on Fennec Pharmaceuticals from $15.00 to $13.00 and set a “buy” rating for the company in a report on Thursday, August 22nd. Craig Hallum decreased their price target on shares of Fennec Pharmaceuticals from $17.00 to $15.00 and set a “buy” rating for the company in a research note on Wednesday, August 14th.

Fennec Pharmaceuticals Stock Down 0.7 %

Shares of NASDAQ:FENC opened at $4.23 on Monday. The firm has a market capitalization of $116.03 million, a P/E ratio of -42.30 and a beta of 0.27. The company has a debt-to-equity ratio of 9.86, a quick ratio of 7.75 and a current ratio of 8.02. The stock has a 50 day moving average price of $4.79 and a 200-day moving average price of $6.02. Fennec Pharmaceuticals has a 52-week low of $3.98 and a 52-week high of $11.92.

Fennec Pharmaceuticals (NASDAQ:FENC) last released its quarterly earnings results on Tuesday, August 13th. The company reported ($0.20) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.06 by ($0.26). Fennec Pharmaceuticals had a negative return on equity of 53.38% and a negative net margin of 2.30%. The company had revenue of $7.26 million during the quarter, compared to the consensus estimate of $13.67 million. During the same period in the previous year, the company earned ($0.21) earnings per share.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in FENC. WINTON GROUP Ltd bought a new position in shares of Fennec Pharmaceuticals during the second quarter valued at $409,000. Russell Investments Group Ltd. increased its stake in Fennec Pharmaceuticals by 71,275.0% during the 1st quarter. Russell Investments Group Ltd. now owns 34,260 shares of the company’s stock valued at $381,000 after purchasing an additional 34,212 shares in the last quarter. Bank of New York Mellon Corp raised its holdings in Fennec Pharmaceuticals by 42.8% in the second quarter. Bank of New York Mellon Corp now owns 68,724 shares of the company’s stock worth $420,000 after buying an additional 20,602 shares during the last quarter. Gendell Jeffrey L lifted its stake in shares of Fennec Pharmaceuticals by 7.1% in the first quarter. Gendell Jeffrey L now owns 302,478 shares of the company’s stock worth $3,364,000 after buying an additional 20,000 shares in the last quarter. Finally, BNP Paribas Financial Markets grew its holdings in shares of Fennec Pharmaceuticals by 67.7% during the first quarter. BNP Paribas Financial Markets now owns 32,769 shares of the company’s stock valued at $364,000 after buying an additional 13,223 shares during the last quarter. Hedge funds and other institutional investors own 55.51% of the company’s stock.

About Fennec Pharmaceuticals

Fennec Pharmaceuticals Inc, a biopharmaceutical company, develops product candidates for use in the treatment of cancer in the United States. Its lead product candidate is the Sodium Thiosulfate, which has completed the Phase III clinical trial for the prevention of cisplatin induced hearing loss or ototoxicity in children.